Suntrust Banks Inc. Sells 533 Shares of Masimo Co. (NASDAQ:MASI)

Suntrust Banks Inc. reduced its stake in Masimo Co. (NASDAQ:MASI) by 10.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,644 shares of the medical equipment provider’s stock after selling 533 shares during the quarter. Suntrust Banks Inc.’s holdings in Masimo were worth $499,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Claybrook Capital LLC purchased a new position in Masimo in the 4th quarter valued at $25,000. Ruggie Capital Group purchased a new position in Masimo in the 4th quarter valued at $33,000. Quantamental Technologies LLC purchased a new position in shares of Masimo during the 4th quarter worth $43,000. Financial Gravity Companies Inc. purchased a new position in shares of Masimo during the 4th quarter worth $49,000. Finally, First Hawaiian Bank raised its holdings in shares of Masimo by 170.0% during the 4th quarter. First Hawaiian Bank now owns 1,080 shares of the medical equipment provider’s stock worth $116,000 after acquiring an additional 680 shares during the period. 83.88% of the stock is owned by hedge funds and other institutional investors.

NASDAQ MASI traded down $0.31 during trading on Wednesday, hitting $126.78. The stock had a trading volume of 325,758 shares, compared to its average volume of 440,552. The company has a market cap of $6.77 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.55 and a beta of 1.19. Masimo Co. has a twelve month low of $88.09 and a twelve month high of $141.05.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 26th. The medical equipment provider reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.11. Masimo had a return on equity of 19.53% and a net margin of 22.55%. The company had revenue of $223.10 million during the quarter, compared to the consensus estimate of $220.96 million. During the same period in the previous year, the company posted $0.72 EPS. Masimo’s revenue was up 7.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Masimo Co. will post 3.08 EPS for the current fiscal year.

In related news, insider Jon Coleman sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $140.00, for a total transaction of $280,000.00. Following the completion of the sale, the insider now owns 13,201 shares in the company, valued at $1,848,140. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Ramshorst David J. Van sold 1,845 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $140.00, for a total value of $258,300.00. Following the completion of the sale, the chief accounting officer now owns 1,695 shares of the company’s stock, valued at approximately $237,300. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,722 shares of company stock valued at $4,832,310. Corporate insiders own 11.50% of the company’s stock.

Several research analysts have recently commented on MASI shares. Needham & Company LLC reiterated a “buy” rating and set a $139.00 price target on shares of Masimo in a report on Friday, February 1st. Zacks Investment Research lowered Masimo from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 31st. Piper Jaffray Companies reissued an “overweight” rating and set a $140.00 price objective on shares of Masimo in a research report on Wednesday, February 27th. Finally, BTIG Research downgraded Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price objective for the company. in a research report on Tuesday, April 16th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $137.75.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/suntrust-banks-inc-trims-holdings-in-masimo-co-masi.html.

Masimo Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Recommended Story: What does the Dow Jones Industrial Average (DJIA) measure?

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.